EDGAR Online

WARNER CHILCOTT LTD

FORM 8-K
(Current report filing)

Filed 03/14/08 for the Period Ending 03/11/08

Telephone	441-295-2244
CIK	0001323854
Symbol	WCRX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Biotechnology & Drugs
Sector	Technology
Fiscal Year	12/31

Powered By EDGAR Online
http://www.edgar-online.com
© Copyright 2008, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report: March 14, 2008
Date of earliest event reported: March 11, 2008

Warner Chilcott Limited
(Exact name of registrant as specified in its charter)

Commission File Number: 1 – 33039

Bermuda **(State or other jurisdiction of incorporation)**	**98-0496358** **(IRS Employer Identification No.)**

Channel House, Suite 3-105, Longfield Road, Southside,
St. David's, Bermuda
(Address of principal executive offices)

(441) 292-0068
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 14, 2008, the Company issued a press release reporting that James G. Andress, a director of the Company, died on Tuesday, March 11, 2008. A copy of the Company's press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
99.1	Press Release issued March 14, 2008 by Warner Chilcott Limited

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

W ARNER C HILCOTT L IMITED

By: /s/ Paul Herendeen
Name: Paul Herendeen
Title: Executive Vice President and Chief Financial Officer

Date: March 14, 2008

Exhibit 99.1

WARNER CHILCOTT REPORTS THE DEATH OF ITS DIRECTOR JAMES ANDRESS

ST. DAVID'S, Bermuda, March 14, 2008 – It is with a profound sense of loss that Warner Chilcott Limited (Nasdaq: WCRX) reports today that Mr. James G. Andress, a director of the Company, died on Tuesday, March 11, 2008.

Roger Boissonneault, Chief Executive Officer, President and Director of Warner Chilcott Limited, issued the following statement:

"We report the loss of Jim Andress with great sadness. Jim was instrumental in the development of this Company. His thoughtful guidance and counsel will be sorely missed. Our deepest sympathies go out to Jim's family."

Mr. Andress was appointed to the Company's board of directors in August of 2006, and at the time of his passing he also served as the co-chairman of the audit committee of the board of directors. Mr. Andress was a former Chairman of the Pharmaceuticals Group, Beecham Group, plc, former Chairman, Healthcare Products and Services of SmithKline Beecham, plc and former President and Chief Operating Officer of Sterling Drug, Inc. From 1996 to 2000, Mr. Andress served as Chairman and Chief Executive Officer of Warner Chilcott PLC (acquired by the Company's predecessor in September 2000). Mr. Andress also served on the board of directors of Sepracor, Inc., XOMA Ltd. and Allstate Insurance Company.

About Warner Chilcott

Warner Chilcott is a leading specialty pharmaceutical company currently focused on the women's healthcare and dermatology segments of the U.S. pharmaceuticals market. We are a fully integrated company with internal resources dedicated to the development, manufacturing and promotion of our products. WCRX-G

Read more on http://www.warnerchilcott.com.

Company Contact: Rochelle Fuhrmann
Investor Relations
973-442-3281
rfuhrmann@wcrx.com